Aldeyra Therapeutics is a mid-clinical stage biotech company focused on exploring its proprietary aldehyde trapping platform as a novel treatment modality for inflammatory and other disorders with substantial unmet medical needs. Aldehyde trapping is based on the concept that by removing excess free aldehydes accumulated in the body, patients with inflammatory or other free aldehyde-causing disorders could be treated. The two initial indications addressed by the company’s lead product, NS2 are Sjögren-Larsson Syndrome (SLS) and acute anterior uveitis. The company filed two INDs in late 4Q14 for Phase II studies in SLS and in non-infectious acute anterior uveitis with data potentially available in 2H15. Both indications are orphan indications, which potentially shorten the time to market and the option of premium pricing. Should the acute anterior uveitis clinical study successful, NS2 could potentially have therapeutic utility in several other inflammatory diseases.